Boston Globe -- Sanofi-Aventis SA’s hostile tender offer for Genzyme Corp. expires at midnight tonight. But so far, the French drug maker has given no indication of how many stockholders have agreed to turn over their shares. Because shares of the Cambridge biotechnology company are still trading above the $69 that Sanofi has offered in its $18.5 billion bid, it is doubtful that many Genzyme investors will opt to cash out.
